The Globe and Mail

OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results

- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively - Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million - ...
The Globe and Mail

UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results

- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively - Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million - ...